Literature DB >> 24900208

Expanded Utility of the β-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic Agents.

Scott C Jeffrey1, Jef De Brabander2, Jamie Miyamoto1, Peter D Senter1.   

Abstract

The β-glucuronide linker has been used for antibody-drug conjugates (ADCs) to deliver amine-containing cytotoxic agents. The linker is stable in circulation, hydrophilic and provides ADCs that are highly active in vitro and in vivo. To extend the utility of the β-glucuronide linker toward phenol-containing drugs, an N,N'-dimethylethylene diamine self-immolative spacer was incorporated with the linker for release of the potent cytotoxic phenol psymberin A. Exposure of the drug-linker to β-glucuronidase resulted in facile drug release. The corresponding ADCs were active and immunologically selective against CD30-positive L540cy and CD70-positive Caki-1 cell lines.

Entities:  

Keywords:  CD30-positive L540cy cell line; CD70-positive Caki-1 cell line; N,N′-dimethylethylene diamine; antibody−drug conjugates; phenolic cytotoxic agents; β-Glucuronide linker

Year:  2010        PMID: 24900208      PMCID: PMC4007898          DOI: 10.1021/ml100039h

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  16 in total

1.  Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin.

Authors:  F M de Groot; L W van Berkom; H W Scheeren
Journal:  J Med Chem       Date:  2000-08-10       Impact factor: 7.446

2.  Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.

Authors:  Svetlana O Doronina; Brian A Mendelsohn; Tim D Bovee; Charles G Cerveny; Stephen C Alley; Damon L Meyer; Ezogelin Oflazoglu; Brian E Toki; Russell J Sanderson; Roger F Zabinski; Alan F Wahl; Peter D Senter
Journal:  Bioconjug Chem       Date:  2006 Jan-Feb       Impact factor: 4.774

3.  Novel peptide linkers for highly potent antibody-auristatin conjugate.

Authors:  Svetlana O Doronina; Tim D Bovee; David W Meyer; Jamie B Miyamoto; Martha E Anderson; Carol A Morris-Tilden; Peter D Senter
Journal:  Bioconjug Chem       Date:  2008-09-20       Impact factor: 4.774

4.  Inhibition of human breast cancer growth by GCP (genistein combined polysaccharide) in xenogeneic athymic mice: involvement of genistein biotransformation by beta-glucuronidase from tumor tissues.

Authors:  Lan Yuan; Chihiro Wagatsuma; Mayumi Yoshida; Takehito Miura; Tomomi Mukoda; Hajime Fujii; Buxiang Sun; Jung-Hwan Kim; Young-Joon Surh
Journal:  Mutat Res       Date:  2003 Feb-Mar       Impact factor: 2.433

5.  Dipeptide-based highly potent doxorubicin antibody conjugates.

Authors:  Scott C Jeffrey; Minh T Nguyen; Jamie B Andreyka; Damon L Meyer; Svetlana O Doronina; Peter D Senter
Journal:  Bioorg Med Chem Lett       Date:  2005-11-03       Impact factor: 2.823

6.  Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates.

Authors:  Scott C Jeffrey; Jamie B Andreyka; Starr X Bernhardt; Kim M Kissler; Toni Kline; Joel S Lenox; Ruth F Moser; Minh T Nguyen; Nicole M Okeley; Ivan J Stone; Xinqun Zhang; Peter D Senter
Journal:  Bioconjug Chem       Date:  2006 May-Jun       Impact factor: 4.774

7.  Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker.

Authors:  Scott C Jeffrey; Minh T Nguyen; Ruth F Moser; Damon L Meyer; Jamie B Miyamoto; Peter D Senter
Journal:  Bioorg Med Chem Lett       Date:  2007-01-27       Impact factor: 2.823

8.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Authors:  Svetlana O Doronina; Brian E Toki; Michael Y Torgov; Brian A Mendelsohn; Charles G Cerveny; Dana F Chace; Ron L DeBlanc; R Patrick Gearing; Tim D Bovee; Clay B Siegall; Joseph A Francisco; Alan F Wahl; Damon L Meyer; Peter D Senter
Journal:  Nat Biotechnol       Date:  2003-06-01       Impact factor: 54.908

Review 9.  Beta-glucuronidase-mediated drug release.

Authors:  Michelle de Graaf; Epie Boven; Hans W Scheeren; Hidde J Haisma; Herbert M Pinedo
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

10.  Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Authors:  Gail D Lewis Phillips; Guangmin Li; Debra L Dugger; Lisa M Crocker; Kathryn L Parsons; Elaine Mai; Walter A Blättler; John M Lambert; Ravi V J Chari; Robert J Lutz; Wai Lee T Wong; Frederic S Jacobson; Hartmut Koeppen; Ralph H Schwall; Sara R Kenkare-Mitra; Susan D Spencer; Mark X Sliwkowski
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 13.312

View more
  7 in total

1.  Reinvestigation of Mycothiazole Reveals the Penta-2,4-dien-1-ol Residue Imparts Picomolar Potency and 8S Configuration.

Authors:  Tyler A Johnson; Joseph D Morris; David A Coppage; Colon V Cook; Lauren N Persi; Marcos A Ogarrio; Taylor C Garcia; Nicole L McIntosh; Erin P McCauley; Joseph Media; Mani Maheshwari; Frederick A Valeriote; Jiajiu Shaw; Phillip Crews
Journal:  ACS Med Chem Lett       Date:  2020-01-02       Impact factor: 4.345

2.  Studies toward the unique pederin family member psymberin: full structure elucidation, two alternative total syntheses, and analogs.

Authors:  Yu Feng; Xin Jiang; Jef K De Brabander
Journal:  J Am Chem Soc       Date:  2012-10-04       Impact factor: 15.419

Review 3.  Linkers Having a Crucial Role in Antibody-Drug Conjugates.

Authors:  Jun Lu; Feng Jiang; Aiping Lu; Ge Zhang
Journal:  Int J Mol Sci       Date:  2016-04-14       Impact factor: 5.923

Review 4.  Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.

Authors:  Rotimi Sheyi; Beatriz G de la Torre; Fernando Albericio
Journal:  Pharmaceutics       Date:  2022-02-11       Impact factor: 6.321

Review 5.  The Chemistry Behind ADCs.

Authors:  Vesela Kostova; Patrice Désos; Jérôme-Benoît Starck; Andras Kotschy
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-07

Review 6.  Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.

Authors:  Nirnoy Dan; Saini Setua; Vivek K Kashyap; Sheema Khan; Meena Jaggi; Murali M Yallapu; Subhash C Chauhan
Journal:  Pharmaceuticals (Basel)       Date:  2018-04-09

Review 7.  Stepping forward in antibody-drug conjugate development.

Authors:  Yiming Jin; Megan A Schladetsch; Xueting Huang; Marcy J Balunas; Andrew J Wiemer
Journal:  Pharmacol Ther       Date:  2021-06-24       Impact factor: 12.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.